3.60
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.63
Aprire:
$3.58
Volume 24 ore:
38,907
Relative Volume:
0.14
Capitalizzazione di mercato:
$31.32M
Reddito:
-
Utile/perdita netta:
$-30.98M
Rapporto P/E:
-0.2948
EPS:
-12.2116
Flusso di cassa netto:
$-31.84M
1 W Prestazione:
+1.98%
1M Prestazione:
+6.19%
6M Prestazione:
-5.51%
1 anno Prestazione:
-53.55%
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Nome
Briacell Therapeutics Corp
Settore
Industria
Telefono
(604) 921-1810
Indirizzo
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Compare BCTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
BCTX
Briacell Therapeutics Corp
|
3.60 | 31.58M | 0 | -30.98M | -31.84M | -12.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
|
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-02-14 | Iniziato | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Borsa (BCTX) Ultime notizie
Book value per share of BriaCell Therapeutics Corp – HAM:8BT - TradingView
BriaCell Therapeutics Corp. (TSX:BCT) Advances as Immunotherapy Pipeline Progress and Clinical Momentum Drive Investor Optimism - kalkine.ca
Net income before discontinued operations of BriaCell Therapeutics Corp – HAM:8BT - TradingView
Free float of BriaCell Therapeutics Corp – HAM:8BT - TradingView
Nature Medicine features a BriaCell trial among 11 shaping medicine in 2026 - Stock Titan
(BCT) Strategic Equity Report (BCT:CA) - Stock Traders Daily
BriaCell Therapeutics Corp (BCTXW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
BriaCell Therapeutics Corp (BCTXW) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Briacell Therapeutics Corp (BCTX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Enterprise value to revenue forward of BriaCell Therapeutics Corp. – NASDAQ:BCTXZ - TradingView
Briacell Therapeutics Corp (BCTX) Peer Comparison – Compare with Others - valueresearchonline.com
Certain Warrants of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. - marketscreener.com
Certain Options of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. - marketscreener.com
BriaCell's Cell-Based ‘Melanoma’ Enters the Skin Cancer Vaccine Conversation - Investing News Network
BriaCell Therapeutics Stock Faces Renewed Pressure as Biotech Volatility Tests Investor Conviction - kalkine.ca
BriaCell Therapeutics Corp. (TSX:BCT) Falls 4.24% as Clinical-Stage Risk and Volatility Pressure Sentiment - kalkine.ca
BriaCell Therapeutics Corp (BCTXW) Peer Comparison – Compare with Others - Value Research
Briacell Therapeutics Corp (BCTX) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
BriaCell Therapeutics Stock Falls Sharply: Can TSX:BCT Stabilize After Renewed Biotech Selling Pressure? - kalkine.ca
BriaCell Therapeutics Stock Falls 6.41%: Why TSX:BCT Is in Focus as Breast and Prostate Cancer Pipeline Advances - kalkine.ca
BriaCell Therapeutics Corp. (TSX:BCT) Gains Momentum as Immunotherapy Pipeline Progress Supports Investor Optimism - kalkine.ca
BriaCell Therapeutics (TSX:BCT) Advances 6.6% on a Run of Pipeline Milestones - kalkine.ca
BriaCell in Focus: TSX: BCT Investors Watch Major Immunotherapy Milestones Ahead of Clinical Data - kalkine.ca
BriaCell Therapeutics Stock Slides 13.31%: Can Clinical Execution Overcome Renewed Biotech Pressure? - kalkine.ca
BriaCell stock choppy on melanoma vaccine milestone - Investing.com
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™ - Yahoo Finance
BCTX Stock Pulls Back As Traders Gauge Biotech Risk - timothysykes.com
BriaCell (BCTXZ) Session: Advances 2.54% to $0.10 in Latest Trading; Next Test: the Price Remains Bounded by the Supplied Support and Resistance in the Latest ReadingShort Term Trading Ideas - vinanet.vn
BriaCell (BCTXL) Stock: Trades in a Narrow Directional Range at $1.00 in Latest Trading; Chart Watch: the Price Remains Bounded by the Supplied Support and Resistance under the Current SnapshotFibonacci Fan - vinanet.vn
Why Did BriaCell Therapeutics (TSX:BCT) Surge 12.37% on 19 August 2026? - kalkine.ca
BriaCell Therapeutics Stock Pops 12% on FDA Clearance for New Prostate Cancer Trial - kalkine.ca
BriaCell (BCTX) Results Breakdown: Reported EPS Tops Expectations in the Current Update; After Earnings - vinanet.vn
BriaCell Therapeutics Stock Rises 3.19% as Phase 3 Breast Cancer Trial and Bria-IMT Progress Draw Investor Interest - kalkine.ca
BriaCell Therapeutics Stock: A Breast-Cancer Immunotherapy Nears Late-Stage Data - kalkine.ca
BCTX Q2 2026 Earnings: Narrower-Than-Expected Loss of -$2.58 Beats Estimates by 47.22%Revenue Recognition Risk - Vinanet
Briacell Therapeutics Corp (BCTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BCTXL Holds Steady at $0.85 as BriaCell Warrant Trades in Tight RangeVolume Nodes - Vinanet
BriaCell Therapeutics Corp (TSX:BCT) Shares Decline as Biotech Uncertainty, Funding Risks and Clinical Execution Concerns Pressure Sentiment - kalkine.ca
Enterprise value to EBIT forward of BriaCell Therapeutics Corp. – BOATS:BCTXL - TradingView
BriaCell Therapeutics Corp. (BCTXZ) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Briacell Therapeutics Corp (BCTX) Stock News Today - TradingKey
BCTX Q2 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline AdvancesRevenue Growth Outlook - vinanet.vn
BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer - Investing News Network
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer - The Manila Times
FDA clearance lets BriaCell test personalized prostate immunotherapy - Stock Titan
BriaCell Therapeutics (BCTX) Rises 3.86% to $3.5 as Immuno-Oncology Interest BuildsVolatility Stop - vinanet.vn
Why Did BriaCell Therapeutics Corp. (TSX:BCT) Stock Fall 5.49% on 31 July 2026? - kalkine.ca
BriaCell Therapeutics (BCTX) Slides 5.2% to $3.44 as Biotech Selling Pressure IntensifiesAscending Triangle - vinanet.vn
BriaCell Therapeutics Warrant (BCTXZ) Holds at $0.09 as Long-Dated Biotech Option Trades FlatPassive Flow - vinanet.vn
BriaCell Therapeutics Corp Revenue Breakdown – TSX:BCT - TradingView
BriaCell Therapeutics Corp. Revenue Breakdown – BOATS:BCTXL - TradingView
Briacell Therapeutics Corp Azioni (BCTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):